Breaking News Instant updates and real-time market news.

ZOM

Zomedica

$1.38

-0.13 (-8.61%)

06:05
12/19/18
12/19
06:05
12/19/18
06:05

Zomedica enters assay development agreement with IncellDx

IncellDx announced it has entered into an assay development agreement with Zomedica to identify and enumerate circulating tumor cells, or CTCs, from canine cancers using its BioINK liquid biopsy reagent platform. The investigational assay will incorporate biomarkers from Zomedica's canine cancer research programs with IncellDx's core BioINK reagents and novel cell cycle capabilities on CTCs. The Celsee Genesis system was designed to provide way for scientists to analyze and interpret cellular behavior and collect critical cell-based information that was previously undetectable. Zomedica entered into a license and supply agreement with Celsee in 2017 to develop and market the Genesis liquid biopsy platform for use by veterinarians as a cancer diagnostic. Celsee also previously partnered with IncellDx on a lung cancer/CTC PD-L1 feasibility study leading to a co-commercialization agreement.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.